Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IMP004
MIFTS: 46

Impetigo

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Impetigo

About this section

MalaCards integrated aliases for Impetigo:

Name: Impetigo 12 76 43 3 44 15 63 73

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:8504
ICD10 33 L01 L01.0 L01.00
ICD9CM 35 684
MeSH 44 D007169
NCIt 50 C99088
SNOMED-CT 68 48277006
UMLS 73 C0021099
Sources

Summaries for Impetigo

About this section
MedlinePlus : 43 Impetigo is a skin infection caused by bacteria. It is usually caused by staphylococcal (staph) bacteria, but it can also be caused by streptococcal (strep) bacteria. It is most common in children between the ages of two and six. It usually starts when bacteria get into a break in the skin, such as a cut, scratch, or insect bite. Symptoms start with red or pimple-like sores surrounded by red skin. These sores can be anywhere, but usually they occur on your face, arms and legs. The sores fill with pus, then break open after a few days and form a thick crust. They are often itchy, but scratching them can spread the sores. Impetigo can spread by contact with sores or nasal discharge from an infected person. You can treat impetigo with antibiotics. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Impetigo is related to impetigo herpetiformis and bullous impetigo, and has symptoms including fever, pruritus and exanthema. An important gene associated with Impetigo is DSG1 (Desmoglein 1), and among its related pathways/superpathways are Lung fibrosis and amb2 Integrin signaling. The drugs Ivermectin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, colon and bone.

Disease Ontology : 12 A pyoderma consisting of three forms of skin lesions having either a thick, adherent, recurrent, dirty yellow crust with an erythematous margin (common or superficial impetigo) or lessions which are superficial, thin-walled, and bullous as found in bullous impetigo. The lesions in bullous (staphylococcal) impetigo, which are always caused by S aureus, are superficial, thin-walled, and bullous.

CDC : 3 Bacteria called group A Streptococcus (group A strep) can cause many different infections. Some of these are common, relatively minor infections, like strep throat. Others are less common, but very serious and even deadly. People can easily spread group A strep to other people. Practicing good hygiene, like washing your hands often, is the best way to protect yourself from group A strep infections.

PubMed Health : 63 About impetigo: Impetigo is an itchy and sometimes painful infection of the outer layers of skin that is especially common in young children. It is caused by bacteria and is highly contagious. For that reason, children who have impetigo are not allowed to return to school or day care until they are no longer contagious – about 24 hours after the start of treatment with antibiotics. Without treatment, it can remain contagious for several weeks.

Wikipedia : 76 Impetigo is a bacterial infection that involves the superficial skin. The most common presentation is... more...

Sources

Related Diseases for Impetigo

About this section

Diseases related to Impetigo via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 impetigo herpetiformis 33.9 ELANE IL36RN PI3
2 bullous impetigo 33.5 CALCA DSG1 EDNRB IL6
3 pyoderma 32.6 DSG1 IL36RN
4 ritter's disease 32.0 DSG1 EDNRB HSF4
5 pustular psoriasis 30.3 ELANE IL36RN PI3
6 psoriasis 30.3 IL36RN IL6 PI3
7 erysipelas 29.7 CALCA ELANE PI3
8 streptococcal toxic-shock syndrome 29.6 IL6 MYOM2
9 toxic shock syndrome 29.3 IL6 MYOM2
10 ecthyma 11.4
11 prolidase deficiency 11.0
12 acute proliferative glomerulonephritis 11.0
13 recessive dystrophic epidermolysis bullosa-generalized other 11.0
14 dermatitis 10.4
15 scabies 10.4
16 pemphigus 10.3
17 glomerulonephritis 10.3
18 dermatitis, atopic 10.3
19 farmer's lung 10.2 ELANE PI3
20 pharyngitis 10.2
21 pustulosis palmaris et plantaris 10.1 ELANE IL36RN
22 engraftment syndrome 10.1 CALCA PI3
23 hypoparathyroidism 10.1
24 miliaria 10.1
25 cellulitis 10.1
26 capillary leak syndrome 10.1 ELANE IL6
27 vulvitis 10.1 ELANE HSF4
28 bacterial sepsis 10.1 CALCA ELANE
29 diabetic foot ulcers 10.1 CALCA IL6
30 acute cholangitis 10.1 CALCA IL6
31 gingival disease 10.1 ELANE IL6
32 nodular goiter 10.1 CALCA IL6
33 newborn respiratory distress syndrome 10.1 ELANE IL6
34 complex regional pain syndrome 10.0 CALCA IL6
35 netherton syndrome 10.0 DSG1 ELANE PI3
36 skin disease 10.0 DSG1 IL36RN PI3
37 psoriasis 14, pustular 10.0
38 miliaria rubra 10.0
39 acute poststreptococcal glomerulonephritis 10.0
40 herpes simplex 10.0
41 extrinsic allergic alveolitis 10.0 IL6 PI3
42 bacterial pneumonia 10.0 ELANE IL6
43 multiple endocrine neoplasia, type iib 10.0 CALCA EDNRB
44 adult respiratory distress syndrome 10.0 ELANE IL6
45 autonomic nervous system disease 10.0 CALCA EDNRB
46 spinal cord disease 10.0 HSF4 IL6
47 bone resorption disease 10.0 CALCA IL6
48 chorioamnionitis 10.0 ELANE IL6
49 esophagitis 10.0 DSG1 IL6
50 gingivitis 10.0 ELANE IL6

Comorbidity relations with Impetigo via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Impetigo:



Diseases related to Impetigo
Sources

Symptoms & Phenotypes for Impetigo

About this section

UMLS symptoms related to Impetigo:


fever, pruritus, exanthema
Sources

Drugs & Therapeutics for Impetigo

About this section

PubMedHealth treatment related to Impetigo: 63

As long as impetigo doesn't spread beyond a small patch of skin, disinfectant solutions or creams are often recommended. But it isn't clear whether they work.Antibiotic creams have proven effective. Antibiotics that are swallowed (oral antibiotics) are usually only prescribed if a child has impetigo on a large area of skin or if several parts of their body are affected. Antibiotic tablets are more likely to have side effects than antibiotic creams. For instance, they may cause gastrointestinal (stomach and bowel) problems.Good hygiene is the key to avoiding infection, especiallywashing hands frequently,not sharing towels, andwashing worn clothing at 60°C (140°F) or higher.It's a good idea to keep the child’s fingernails trimmed very short so they can't scratch themselves as much.

Drugs for Impetigo (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Not Applicable 70288-86-7 6474909
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Permethrin Approved, Investigational Phase 4,Not Applicable 52645-53-1 40326
4
Fusidic Acid Approved, Investigational Phase 4,Phase 3 6990-06-3 3000226
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antiparasitic Agents Phase 4,Not Applicable
9 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
10
Mupirocin Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 12650-69-0 446596
11
Menthol Approved Phase 2, Phase 3 2216-51-5 16666
12
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
13
Zinc Approved, Investigational Phase 3 7440-66-6
14 Dermatologic Agents Phase 2, Phase 3,Not Applicable
15 Terpin Phase 2, Phase 3
16 Respiratory System Agents Phase 2, Phase 3
17 Expectorants Phase 2, Phase 3
18 Antipruritics Phase 2, Phase 3
19 methicillin Phase 3,Not Applicable
20 Micronutrients Phase 3
21 Trace Elements Phase 3
22
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
23 Papaya Approved Phase 1
24
Diethylcarbamazine Approved, Investigational, Vet_approved Not Applicable 90-89-1 3052
25
Albendazole Approved, Vet_approved Not Applicable 54965-21-8 2082
26
Chlorhexidine Approved, Vet_approved Not Applicable 55-56-1 2713 9552079
27 Vaccines
28 Lipoxygenase Inhibitors Not Applicable
29 Antiprotozoal Agents Not Applicable
30 Liver Extracts Not Applicable
31 Antimitotic Agents Not Applicable
32 Anthelmintics Not Applicable
33 Chlorhexidine gluconate Not Applicable
34 Disinfectants Not Applicable
35 Eusol Not Applicable
36 Anti-Infective Agents, Local Not Applicable
37 Sodium hypochlorite Not Applicable

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Completed NCT02775617 Phase 4 Ivermectin;Azithromycin;Permethrin
2 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Completed NCT01126268 Phase 4 Retapamulin (Altabax)
3 Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
4 Group A Pharyngitis in Children: The GASPARD Study Recruiting NCT03264911 Phase 4 Amoxicillin or Placebo
5 Fucidin® Cream in the Treatment of Impetigo Terminated NCT00986856 Phase 4 Fucidin® cream
6 Citriodiol® and Impetigo Unknown status NCT01611909 Phase 2, Phase 3 p-menthane-3,8-diol oil
7 Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment Completed NCT00133848 Phase 3 SB-275833 ointment, 1%
8 Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Completed NCT02090764 Phase 3 Ozenoxacin;Placebo
9 Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Completed NCT01397461 Phase 3 ozenoxacin placebo;retapamulin 1% ointment;ozenoxacin 1% cream
10 Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Completed NCT01670032 Phase 2, Phase 3 Experimental: CD07223 1.5 % Topical Gel BID;Experimental: CD07223 1.5% Topical Gel TID;Placebo Comparator: CD07223 vehicle gel BID;Placebo Comparator: CD07223 vehicle gel TID
11 Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo Completed NCT00133874 Phase 3 SB-275833 ointment, 1%
12 Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA Completed NCT00852540 Phase 3 Retpamulin Ointment, 1%;Linezolid
13 Immunological and Clinical Responses to Zinc in Children With Diarrhoea Completed NCT00408356 Phase 3 Zinc
14 Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients Completed NCT01171326 Phase 2 Topical Minocycline Foam FXFM244
15 A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo Completed NCT01803035 Phase 2 LTX-109 1 %;LTX-109 2 %;Placebo gel
16 Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo Completed NCT03429595 Phase 2 ATx201
17 Safety and Efficacy of Topical NVC-422 Gel in Impetigo Completed NCT01367314 Phase 2 NVC-422
18 Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Completed NCT00626795 Phase 2 TD1414 2% cream;TD1414 2% cream;Bactroban® (mupirocin) 2% cream
19 The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Completed NCT00758862 Phase 2 2% TD1414 Cream
20 A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection Completed NCT01223222 Phase 2 LTX-109
21 The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT01943136 Phase 1 papaya 1% extract ointment;mupirocin 2% ointment
22 EU PV for Retapamulin-Prescribing Completed NCT01153828 Retapamulin;Co-prescription of retapamulin and topical mupirocin;Co-prescription of retapamulin and topical fusidic acid
23 Surveillance of Streptococcal Infections in Children in India Completed NCT00342199
24 Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 Not Applicable 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
25 Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory Completed NCT00884728
26 The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) Completed NCT00822276
27 United States Pharmacovigilence Retapamulin-Prescribing Completed NCT01153880 Retapamulin;Co-prescription of retapamulin and topical mupirocin
28 ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) Completed NCT01445600 ALTARGO(retapamulin)
29 The Natural History of Community-Associated MRSA Infections and Decolonization Strategies Completed NCT00513799 Not Applicable Mupirocin ointment
30 Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo Active, not recruiting NCT02902822 Not Applicable

Search NIH Clinical Center for Impetigo

Cochrane evidence based reviews: impetigo

Sources

Genetic Tests for Impetigo

About this section
Sources

Anatomical Context for Impetigo

About this section

MalaCards organs/tissues related to Impetigo:

41
Skin, Colon, Bone, T Cells, Liver, Heart, Spinal Cord
Sources

Publications for Impetigo

About this section

Articles related to Impetigo:

(show top 50) (show all 504)
# Title Authors Year
1
Impetigo: A need for new therapies in a world of increasing antimicrobial resistance. ( 29063621 )
2018
2
Granulocyte/Monocyte Adsorption Apheresis as a Novel Therapeutic Approach in the Treatment of an Impetigo Herpetiformis Case. ( 29318775 )
2018
3
Bilateral Periorbital Impetigo Inducing Significant Dermatitis and Cicatricial Eyelid Changes in an Adult. ( 29784090 )
2018
4
Building capacity in primary care: the implementation of a novel 'Pharmacy First' scheme for the management of UTI, impetigo and COPD exacerbation. ( 29362007 )
2018
5
Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. ( 29898217 )
2018
6
Allergic contact dermatitis from formaldehyde mimicking impetigo and initiating rosacea. ( 29611264 )
2018
7
Ozenoxacin: a novel drug discovery for the treatment of impetigo. ( 29732990 )
2018
8
Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment. ( 29849579 )
2018
9
Atopic dermatitis complicated by severe impetigo in a Syrian refugee infant. ( 29764821 )
2018
10
Ozenoxacin: A Novel Topical Quinolone for Impetigo. ( 29962213 )
2018
11
PUSTULAR DERMATITIS CAUSED BY IMPETIGO IN RED-TAILED MONKEYS ( CERCOPITHECUS ASCANIUS). ( 29517455 )
2018
12
Scabies and impetigo in Timor-Leste: A school screening study in two districts. ( 29852002 )
2018
13
Randomised trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. ( 29985978 )
2018
14
An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up. ( 30028004 )
2018
15
Secondary syphilis presented with impetigo-like lesions: a rare case report. ( 30094832 )
2018
16
Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab. ( 30105995 )
2018
17
Is impetigo a missed opportunity for scabies treatment? ( 30161116 )
2018
18
Anetodermic lesions following pityriasis rosea and impetigo. ( 30229641 )
2018
19
Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. ( 30346521 )
2018
20
Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials. ( 30365584 )
2018
21
The Epidemiology of Scabies and Impetigo in Relation to Demographic and Residential Characteristics: Baseline Findings from the Skin Health Intervention Fiji Trial. ( 28722612 )
2017
22
Impetigo ( 28613693 )
2017
23
Recurrent impetigo herpetiformis: case report. ( 28979621 )
2017
24
Concurrent pyogenic granuloma and bullous impetigo of a pregnant woman's finger. ( 28329529 )
2017
25
Diagnosis and management of impetigo. ( 28178083 )
2017
26
Community-Based Prescribing for Impetigo in Remote Australia: An Opportunity for Antimicrobial Stewardship. ( 28748178 )
2017
27
Are scabies and impetigo "normalised"? A cross-sectional comparative study of hospitalised children in northern Australia assessing clinical recognition and treatment of skin infections. ( 28671945 )
2017
28
Management of impetigo and cellulitis: Simple considerations for promoting appropriate antibiotic use in skin infections. ( 28807958 )
2017
29
Ozenoxacin Cream, 1% - Topical Treatment of Impetigo. ( 28270312 )
2017
30
Bullous impetigo during interstitial pneumonitis. ( 29050448 )
2017
31
Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. ( 29255730 )
2017
32
Incremental Contributions of FbaA and Other Impetigo-Associated Surface Proteins to Fitness and Virulence of a Classical Group A Streptococcal Skin Strain. ( 28808160 )
2017
33
Two highly divergent lineages of exfoliative toxin B-encoding plasmids revealed in impetigo strains of Staphylococcus aureus. ( 28579477 )
2017
34
Staphylococcal bullous impetigo in a neonate. ( 27458596 )
2016
35
The Prevalence of Scabies and Impetigo in the Solomon Islands: A Population-Based Survey. ( 27348119 )
2016
36
Impetigo and scabies - Disease burden and modern treatment strategies. ( 27180311 )
2016
37
Impetigo, Erysipelas and Cellulitis ( 26866211 )
2016
38
Impetigo Herpetiformis Complicated with Intrauterine Growth Restriction Treated Successfully with Granulocyte and Monocyte Apheresis. ( 27573023 )
2016
39
A Case of Tinea Corporis due to Trichophyton tonsurans that Manifested as Impetigo. ( 27581776 )
2016
40
The Importance of Scabies Coinfection in the Treatment Considerations for Impetigo. ( 26599569 )
2016
41
Where to from here? The treatment of impetigo in children as resistance to fusidic acid emerges. ( 27736855 )
2016
42
An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control study. ( 27613059 )
2016
43
"EB, or Not EB?" Neonatal Desquamative Impetigo in a Degloving Pattern. ( 26821848 )
2016
44
Bullous impetigo and pregnancy: Case report and review of blistering conditions in pregnancy. ( 27617460 )
2016
45
Tissue tropisms in group A Streptococcus: what virulence factors distinguish pharyngitis from impetigo strains? ( 26895573 )
2016
46
Staphylococcus aureus penetrate the interkeratinocyte spaces created by skin-infiltrating neutrophils in a mouse model of impetigo. ( 27862501 )
2016
47
Crusted impetigo-like lesion on the face: a case of IgG/IgA pemphigus. ( 27879012 )
2016
48
Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. ( 27659511 )
2016
49
Case of bullous impetigo with enormous bulla developing into staphylococcal scalded skin syndrome. ( 26603272 )
2016
50
Impetigo contagiosa in a zosteriform pattern. ( 27333861 )
2016
Sources

Variations for Impetigo

About this section
Sources

Expression for Impetigo

About this section
Search GEO for disease gene expression data for Impetigo.
Sources

Pathways for Impetigo

About this section

Pathways related to Impetigo according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Lung fibrosis 1
11.06 CALCA IL6
2
amb2 Integrin signaling 1
10.84 ELANE IL6
3
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.61 CALCA IL6
4
Endothelin Pathways 1
10.15 CALCA EDNRB
Sources

GO Terms for Impetigo

About this section

Cellular components related to Impetigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornified envelope GO:0001533 8.62 DSG1 PI3

Biological processes related to Impetigo according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.67 CALCA IL36RN IL6
2 cellular response to lipopolysaccharide GO:0071222 9.5 EDNRB IL36RN IL6
3 regulation of blood pressure GO:0008217 9.48 CALCA EDNRB
4 positive regulation of interleukin-6 production GO:0032755 9.46 IL36RN IL6
5 positive regulation of smooth muscle cell proliferation GO:0048661 9.43 ELANE IL6
6 antimicrobial humoral response GO:0019730 9.4 ELANE PI3
7 monocyte chemotaxis GO:0002548 9.37 CALCA IL6
8 response to pain GO:0048265 9.26 CALCA EDNRB
9 vasodilation GO:0042311 9.16 CALCA EDNRB
10 negative regulation of bone resorption GO:0045779 8.96 CALCA IL6
11 negative regulation of chemokine biosynthetic process GO:0045079 8.62 ELANE IL6
Sources

Sources for Impetigo

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....